Zentalis Pharmaceuticals, Inc.
ZNTL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001725160
In the last 90 days, Zentalis Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 0 sales; 114 institutions reported holding it in 13F filings for Q2 2026, worth $228.9M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Zentalis Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 1 filing
- 1 insider, $15.2M in total
- Open-market sells
- 0 filings
- Insiders trading
- 1
- Net value
- +$15.2M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Zentalis Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Walters Group | 10% Owner | 17,844,973 | Aug 19, 2026 | 2 |
| Walters William Thurman | 10% Owner | 17,844,973 | Aug 19, 2026 | 2 |
| Walters Susan Berkley | 10% Owner | 17,844,973 | Aug 19, 2026 | 2 |
| Myers Scott Dunseth | Director | 395,895 | Jun 18, 2026 | 1 |
| Walker Luke Nathaniel | Director | 201,384 | Jun 18, 2026 | 1 |
| Johnson David Michael | Director | 307,521 | Jun 18, 2026 | 1 |
| Skvarka Jan | Director | 264,254 | Jun 18, 2026 | 1 |
| Kariuki Enoch | Director | 194,465 | Jun 18, 2026 | 1 |
| Campbell Shannon | Director | 114,200 | May 27, 2026 | 1 |
| Eastland Julia Marie | CEO & President | 79,133 | Feb 10, 2026 | 2 |
| Bruns Ingmar | Chief Medical Officer | 33,332 | Feb 10, 2026 | 2 |
| Vultaggio Vincent | PAO and PFO | 146,506 | Feb 10, 2026 | 3 |
| Bucher James B | Chief Legal Officer | – | Jan 9, 2026 | 2 |
| Matrix Capital Management Company, LP | 10% Owner | 6,459,973Indirect | Dec 15, 2025 | 1 |
| Goel David E. | 10% Owner | 6,459,973Indirect | Dec 15, 2025 | 1 |
| Lackner Mark | Chief Scientific Officer | 512,856 | Feb 5, 2025 | 0 |
| Paul Andrea | Chief Legal Officer | 1,070,784 | Feb 5, 2025 | 0 |
| Gallagher Cam | President, Interim CFO | 633,680 | May 31, 2024 | 0 |
| Hausman Diana | Chief Medical Officer | 373,876 | May 9, 2024 | 0 |
| Epperly Melissa B, | Chief Financial Officer | 451,449 | Feb 12, 2024 | 0 |
| Blackwell Kimberly | Chief Executive Officer | 484,145 | Feb 5, 2024 | 0 |
| Bunker Kevin D. | Chief Scientific Officer | 834,931 | Dec 21, 2023 | 0 |
| Brownstein Carrie | Chief Medical Officer | 105,685 | Oct 6, 2023 | 0 |
| Roth Iris | Chief Operating Officer | 52,500 | Mar 2, 2023 | 0 |
| Sun Anthony Y | President & CEO | 1,175,589 | Apr 5, 2022 | 0 |
| Voliotis Dimitris | SVP, Clinical Development | 15,978 | Feb 14, 2022 | 0 |
| Pinto Alexis | Chief Legal Officer | 22,240 | Feb 14, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2025 (view filing) | Apr 30 | Same day | Myers Scott DunsethDirector | PPurchase | +21.0K | $1.40 | +$29.4K | +8.1%281.2K after | |
| Dec 15, 2025 (view filing)5:24 PM ET | Dec 15 | Same day | Matrix Capital Management Company, LP and 1 other10% Owner | SSaleCommon Stock, par value $0.001 per share | −7.50M | $1.33 | −$9.97M | −53.7%6.46M after | |
| Jan 8, 2026 (view filing)4:57 PM ET | Dec 31, 2025 | 8 daysLate | Walters Group and 2 others10% Owner | PPurchase | +6.46M | $1.20 | +$7.75M | +91.6%13.5M after | |
| Feb 4, 2026 (view filing) | Feb 2-3 | 2 days | Vultaggio VincentPAO and PFO | SSale | −3.10K | $2.54 | −$7.88K | −1.6%186.7K after | 2 lots10b5-1 |
| Feb 10, 2026 (view filing) | Feb 6-9 | 4 days | Eastland Julia MarieCEO & President | SSale | −8.76K | $2.43 | −$21.2K | −10.0%79.1K after | 2 lots |
| Feb 10, 2026 (view filing) | Feb 6-9 | 4 days | Bruns IngmarChief Medical Officer | SSale | −3.30K | $2.43 | −$8.00K | −9.0%33.3K after | 2 lots |
| Feb 10, 2026 (view filing) | Feb 6-10 | 4 days | Vultaggio VincentPAO and PFO | SSale | −40.2K | $2.42 | −$97.5K | −21.5%146.5K after | 3 lots10b5-1 |
| Aug 19, 2026 (view filing)6:11 PM ET | Aug 14 | 5 daysLate | Walters Group and 2 others10% Owner | PPurchase | +4.33M | $3.50 | +$15.2M | +32.1%17.8M after |